MS treatment gains favor relapsing over progressive forms
By MS Buddy ·
Summarized from The New England journal of medicine, Jul 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
Review · people with relapsing and progressive forms of MS
Research by Stephen Hauser at the University of California, San Francisco.
How do treatment options differ for relapsing and progressive MS?
Key Takeaway
Treatments have improved outcomes for relapsing MS, but options for progressive MS remain limited.

What They Found
This review describes how MS damages myelin (the protective covering around nerves). Nerve damage also plays a major role in long-term disability. Treatments that change immune activity have improved outcomes for people with relapsing MS. Treatment options for progressive MS remain limited. The review also stresses the importance of symptom care and lifestyle support.
Who Should Care and Why
This review is about people with MS, not a new group of study participants. It discusses treatment gains for people with relapsing forms of MS. It also describes the limited options for people with progressive forms. People with MS symptoms may find its discussion of symptom care relevant. The review links symptom care and lifestyle support to quality of life and disability.
Important Considerations
This is a review, not a report of a new treatment test. It does not give a sample size or compare specific treatments. It does not show that a new treatment prevents worsening or repairs myelin.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in The New England journal of medicine by . Reproduced from the PubMed record.
Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, causing episodes of neurologic dysfunction and often gradual disease progression. The immune system primarily targets myelin, the protective covering of nerve fibers, leading to inflammation and damage, and secondary neurodegeneration is a major cause of long-term disability. Common symptoms include vision problems, sensory disturbances, muscle weakness, balance difficulties, and bladder dysfunction. Important advances in treatment have improved outcomes in patients with relapsing forms of multiple sclerosis, particularly through highly effective immune-modifying therapies such as CD20-targeting monoclonal antibodies. However, treatment options for progressive forms remain limited, which highlights the need for therapies that can prevent progression and promote myelin repair. Comprehensive symptom management and lifestyle support are also essential to maintaining quality of life and reducing disability.
Categories
Explore more research
Related MS research

11/14/2026
In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.
Read More
11/15/2026
A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older
Read More
11/12/2026
In a study of 601 people in Japan after first optic nerve inflammation, some later had MS. Others ha
Read More
11/13/2026
From 2013 to 2024, more people with MS in Poland received treatment and started sooner. Stronger dru
Read More
11/12/2026
In 82 older adults with MS, more lesions on the brain's outer layer weakened links between resting b
Read More
1/1/2027
In treatment trials, Ocrevus lowered disability worsening risk for a high-risk group with relapsing
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
